Build Your Comparison

Side-by-side financial analysis
ACOG logo
ACOG
AVXL logo
AVXL
SAVA logo
SAVA
PRAX logo
PRAX
ACIU logo
ACIU
Try popular comparisons:

Stock Comparison

ACOG vs AVXL vs SAVA vs PRAX vs ACIU

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ACOG
Alpha Cognition Inc. Common Stock

Financial - Conglomerates

Financial ServicesNASDAQ • CA
Market Cap$98M
5Y Perf.-4.8%
AVXL
Anavex Life Sciences Corp.

Biotechnology

HealthcareNASDAQ • US
Market Cap$232M
5Y Perf.-73.6%
SAVA
Cassava Sciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$64M
5Y Perf.-40.6%
PRAX
Praxis Precision Medicines, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7.70B
5Y Perf.+232.5%
ACIU
AC Immune S.A.

Biotechnology

HealthcareNASDAQ • CH
Market Cap$235M
5Y Perf.-32.1%

ACOG vs AVXL vs SAVA vs PRAX vs ACIU — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ACOG logoACOG
AVXL logoAVXL
SAVA logoSAVA
PRAX logoPRAX
ACIU logoACIU
IndustryFinancial - ConglomeratesBiotechnologyBiotechnologyBiotechnologyBiotechnology
Market Cap$98M$232M$64M$7.70B$235M
Revenue (TTM)$11M$0.00$0.00$4M
Net Income (TTM)$-25M$-40M$-106M$-327M$-70M
Gross Margin86.4%100.0%
Operating Margin-250.1%-19.3%
Total Debt$0.00$0.00$0.00$110K$5M
Cash & Equiv.$66M$103M$129M$357M$27M

ACOG vs AVXL vs SAVA vs PRAX vs ACIULong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ACOG
AVXL
SAVA
PRAX
ACIU
StockNov 24Jun 26Return
Alpha Cognition Inc… (ACOG)10095.2-4.8%
Anavex Life Science… (AVXL)10026.4-73.6%
Cassava Sciences, I… (SAVA)10059.4-40.6%
Praxis Precision Me… (PRAX)100332.5+232.5%
AC Immune S.A. (ACIU)10067.9-32.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: ACOG vs AVXL vs SAVA vs PRAX vs ACIU

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AVXL leads in 2 of 6 categories (5-stock set), making it the strongest pick for growth and revenue expansion and operational efficiency and capital deployment. Alpha Cognition Inc. Common Stock is the stronger pick specifically for capital preservation and lower volatility. SAVA and PRAX also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇AVXL emerged as the overall leader. Track its performance:
ACOG
Alpha Cognition Inc. Common Stock
The Banking Pick

ACOG is the #2 pick in this set and the best alternative if long-term compounding and defensive is your priority.

  • -11.3% 10Y total return vs PRAX's -36.1%
  • Beta 1.29, current ratio 8.65x
  • Beta 1.29 vs SAVA's 1.92
Best for: long-term compounding and defensive
AVXL
Anavex Life Sciences Corp.
The Income Pick

AVXL carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 0 yrs, beta 1.77
  • -34.9% revenue growth vs SAVA's -5.4%
  • -35.0% ROA vs SAVA's -75.3%
Best for: income & stability
SAVA
Cassava Sciences, Inc.
The Quality Compounder

SAVA ranks third and is worth considering specifically for quality.

  • 5.4% margin vs ACIU's -19.7%
Best for: quality
PRAX
Praxis Precision Medicines, Inc.
The Defensive Pick

PRAX is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
  • +491.9% vs AVXL's -69.6%
Best for: sleep-well-at-night
ACIU
AC Immune S.A.
The Growth Play

ACIU is the clearest fit if your priority is growth exposure.

  • Rev growth -86.9%, EPS growth -37.3%, 3Y rev CAGR -3.2%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthAVXL logoAVXL-34.9% revenue growth vs SAVA's -5.4%
Quality / MarginsSAVA logoSAVA5.4% margin vs ACIU's -19.7%
Stability / SafetyACOG logoACOGBeta 1.29 vs SAVA's 1.92
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)PRAX logoPRAX+491.9% vs AVXL's -69.6%
Efficiency (ROA)AVXL logoAVXL-35.0% ROA vs SAVA's -75.3%

ACOG vs AVXL vs SAVA vs PRAX vs ACIU — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ACOGAlpha Cognition Inc. Common Stock
FY 2025
Service
100.0%$433,221
AVXLAnavex Life Sciences Corp.

Segment breakdown not available.

SAVACassava Sciences, Inc.

Segment breakdown not available.

PRAXPraxis Precision Medicines, Inc.
FY 2024
License
76.8%$9M
Upfront Payment
23.2%$3M
ACIUAC Immune S.A.

Segment breakdown not available.

ACOG vs AVXL vs SAVA vs PRAX vs ACIU — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACOGLAGGINGACIU

Income & Cash Flow (Last 12 Months)

ACOG leads this category, winning 3 of 5 comparable metrics.

ACOG and PRAX operate at a comparable scale, with $11M and $0 in trailing revenue. ACOG is the more profitable business, keeping -2.3% of every revenue dollar as net income compared to ACIU's -19.7%.

MetricACOG logoACOGAlpha Cognition I…AVXL logoAVXLAnavex Life Scien…SAVA logoSAVACassava Sciences,…PRAX logoPRAXPraxis Precision …ACIU logoACIUAC Immune S.A.
RevenueTrailing 12 months$11M$0$0$4M
EBITDAEarnings before interest/tax-$27M-$39M-$110M-$357M-$67M
Net IncomeAfter-tax profit-$25M-$40M-$106M-$327M-$70M
Free Cash FlowCash after capex-$30M-$34M-$84M-$283M-$70M
Gross MarginGross profit ÷ Revenue+86.4%+100.0%
Operating MarginEBIT ÷ Revenue-2.5%-19.3%
Net MarginNet income ÷ Revenue-2.3%-19.7%
FCF MarginFCF ÷ Revenue-2.8%-19.6%
Rev. Growth (YoY)Latest quarter vs prior year-70.3%
EPS Growth (YoY)Latest quarter vs prior year-146.2%+54.4%+62.1%+2.7%+6.7%
ACOG leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

Evenly matched — ACOG and SAVA and PRAX each lead in 1 of 3 comparable metrics.
MetricACOG logoACOGAlpha Cognition I…AVXL logoAVXLAnavex Life Scien…SAVA logoSAVACassava Sciences,…PRAX logoPRAXPraxis Precision …ACIU logoACIUAC Immune S.A.
Market CapShares × price$98M$232M$64M$7.7B$235M
Enterprise ValueMkt cap + debt − cash$32M$129M-$65M$7.3B$207M
Trailing P/EPrice ÷ TTM EPS-5.38x-4.63x-2.54x-19.77x-2.63x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue9.57x52.43x
Price / BookPrice ÷ Book value/share1.78x2.25x0.42x6.83x4.13x
Price / FCFMarket cap ÷ FCF
Evenly matched — ACOG and SAVA and PRAX each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

ACOG leads this category, winning 4 of 8 comparable metrics.

AVXL delivers a -38.8% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-102 for ACIU. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACIU's 0.10x. On the Piotroski fundamental quality scale (0–9), ACOG scores 4/9 vs ACIU's 2/9, reflecting mixed financial health.

MetricACOG logoACOGAlpha Cognition I…AVXL logoAVXLAnavex Life Scien…SAVA logoSAVACassava Sciences,…PRAX logoPRAXPraxis Precision …ACIU logoACIUAC Immune S.A.
ROE (TTM)Return on equity-54.1%-38.8%-95.8%-43.0%-101.6%
ROA (TTM)Return on assets-41.8%-35.0%-75.3%-40.2%-38.7%
ROICReturn on invested capital-32.4%-6.3%-65.0%-99.2%
ROCEReturn on capital employed-38.4%-47.8%-99.9%-49.3%-72.6%
Piotroski ScoreFundamental quality 0–942232
Debt / EquityFinancial leverage0.00x0.10x
Net DebtTotal debt minus cash-$66M-$103M-$129M-$357M-$22M
Cash & Equiv.Liquid assets$66M$103M$129M$357M$27M
Total DebtShort + long-term debt$0$0$0$110,000$5M
Interest CoverageEBIT ÷ Interest expense-482.85x
ACOG leads this category, winning 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — ACOG and PRAX each lead in 3 of 6 comparable metrics.

A $10,000 investment in ACOG five years ago would be worth $8,873 today (with dividends reinvested), compared to $1,191 for AVXL. Over the past 12 months, PRAX leads with a +491.9% total return vs AVXL's -69.6%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs AVXL's -33.9% — a key indicator of consistent wealth creation.

MetricACOG logoACOGAlpha Cognition I…AVXL logoAVXLAnavex Life Scien…SAVA logoSAVACassava Sciences,…PRAX logoPRAXPraxis Precision …ACIU logoACIUAC Immune S.A.
YTD ReturnYear-to-date-3.1%-32.1%-36.8%-6.9%-31.3%
1-Year ReturnPast 12 months-34.4%-69.6%-37.7%+491.9%+11.6%
3-Year ReturnCumulative with dividends-11.3%-71.1%-62.5%+1757.4%+8.5%
5-Year ReturnCumulative with dividends-11.3%-88.1%-87.8%-14.2%-68.8%
10-Year ReturnCumulative with dividends-11.3%-38.3%-38.0%-36.1%-85.2%
CAGR (3Y)Annualised 3-year return-3.9%-33.9%-27.9%+164.8%+2.7%
Evenly matched — ACOG and PRAX each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ACOG and PRAX each lead in 1 of 2 comparable metrics.

ACOG is the less volatile stock with a 1.29 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 72.7% from its 52-week high vs AVXL's 17.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricACOG logoACOGAlpha Cognition I…AVXL logoAVXLAnavex Life Scien…SAVA logoSAVACassava Sciences,…PRAX logoPRAXPraxis Precision …ACIU logoACIUAC Immune S.A.
Beta (5Y)Sensitivity to S&P 5001.29x1.77x1.92x1.55x1.69x
52-Week HighHighest price in past year$11.54$13.99$4.98$366.52$4.00
52-Week LowLowest price in past year$4.50$2.41$1.27$37.19$1.65
% of 52W HighCurrent price vs 52-week peak+54.6%+17.9%+26.5%+72.7%+57.8%
RSI (14)Momentum oscillator 0–10050.936.842.731.934.7
Avg Volume (50D)Average daily shares traded42K1.0M134K396K294K
Evenly matched — ACOG and PRAX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ACOG as "Buy", AVXL as "Buy", SAVA as "Buy", PRAX as "Buy", ACIU as "Buy". Consensus price targets imply 340.0% upside for AVXL (target: $11) vs 122.2% for ACOG (target: $14).

MetricACOG logoACOGAlpha Cognition I…AVXL logoAVXLAnavex Life Scien…SAVA logoSAVACassava Sciences,…PRAX logoPRAXPraxis Precision …ACIU logoACIUAC Immune S.A.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$14.00$11.00$607.15$7.00
# AnalystsCovering analysts11312169
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ACOG leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.

Best OverallAlpha Cognition Inc. Common… (ACOG)Leads 2 of 6 categories
Loading custom metrics...

ACOG vs AVXL vs SAVA vs PRAX vs ACIU: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is ACOG or AVXL or SAVA or PRAX or ACIU a better buy right now?

For growth investors, AC Immune S.

A. (ACIU) is the stronger pick with -86. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Alpha Cognition Inc. Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ACOG or AVXL or SAVA or PRAX or ACIU?

Over the past 5 years, Alpha Cognition Inc.

Common Stock (ACOG) delivered a total return of -11. 3%, compared to -88. 1% for Anavex Life Sciences Corp. (AVXL). Over 10 years, the gap is even starker: ACOG returned -11. 3% versus ACIU's -85. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ACOG or AVXL or SAVA or PRAX or ACIU?

By beta (market sensitivity over 5 years), Alpha Cognition Inc.

Common Stock (ACOG) is the lower-risk stock at 1. 29β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 49% more volatile than ACOG relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 10% for AC Immune S. A. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ACOG or AVXL or SAVA or PRAX or ACIU?

By revenue growth (latest reported year), AC Immune S.

A. (ACIU) is pulling ahead at -86. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -37. 3% for AC Immune S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ACOG or AVXL or SAVA or PRAX or ACIU?

Anavex Life Sciences Corp.

(AVXL) is the more profitable company, earning 0. 0% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVXL leads at 0. 0% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ACOG or AVXL or SAVA or PRAX or ACIU?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is ACOG or AVXL or SAVA or PRAX or ACIU better for a retirement portfolio?

For long-horizon retirement investors, Alpha Cognition Inc.

Common Stock (ACOG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACOG: -11. 3%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ACOG and AVXL and SAVA and PRAX and ACIU?

These companies operate in different sectors (ACOG (Financial Services) and AVXL (Healthcare) and SAVA (Healthcare) and PRAX (Healthcare) and ACIU (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.